Insights

How did the CSL (ASX:CSL) share price respond last earnings season?

How did the company’s shares react following its H1 FY21 result?
The post How did the CSL (ASX:CSL) share price respond last earnings season? appeared first on The Motley Fool Australia. –

The CSL Limited (ASX: CSL) share price has climbed 8% over the past month, reflecting renewed investor optimism of late. It’s no secret that the company is due to report its much-anticipated FY21 full-year results on Wednesday.

After Monday’s market close, the global biotech’s shares finished the day flat at $297.49. In early trade on Tuesday, their price has dropped 0.29% to $296.64.

Let’s take a peek to see how CSL performed for the first half of FY21 and how its share price reacted.

What did CSL report for H1 FY21?

During mid-February, CSL delivered its first-half result, citing a strong growth despite COVID-19 challenges.

Here’s a summary of the financial numbers that CSL posted for its last earnings season.

Total revenue up 16.9% to US$5,739 million driven by 9% increase in CSL Behring revenue and a 38% jump in Seqirus revenue

Earnings before interest and tax (EBIT) up 44.4% to US$2,358 million
Net Profit After Tax (NPAT) up 46.2% to US$1,810 million

Following the release, CSL shares rocketed from $279.51 on 17 February to an intraday high of $295.30 on 18 February. This represents a jump of around 5.6% for the blue-chip company.

However, investors were quick to take profit off the table as CSL flagged plasma collection issues in its report. In the weeks after, the company’s shares were trading at a 52-week low of $242.00 apiece.

What should investors look out for this earnings season?

According to Goldman Sachs, CSL is expected to negatively surprise the market tomorrow on its FY21 result. The broker notes that the result is set to be challenging but, in itself, a minor focus amid the COVID-19 chaos.

CSL reaffirmed its earnings to be within 3% to 8% ahead for the FY21 full-year, despite delivering a 25% increase at H1 FY21. This points to an earnings decline of 47% to 58% in the second half.

Cost pressures are also likely to persist into FY22 as CSL aims to recover the collection of plasma to pre-pandemic levels.

In addition, the development of mRNA-based flu vaccines could be a concern for the company’s Seqirus business. The threat of competitive entry into this market will be carefully watched. 

CSL share price snapshot

Year-to-date, the CSL share price has continued to move sideways, reflecting a 5% gain for the period. When looking at a longer time frame, the company’s shares are up 6% over the last 12 months.

CSL commands a market capitalisation of roughly $135.4 billion, making it the third largest company on the ASX.

The post How did the CSL (ASX:CSL) share price respond last earnings season? appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

ASX 200 Weekly Wrap: New records just keep coming for the ASX 200

If you invested $1,000 in CSL (ASX:CSL) shares a decade ago, here’s what it would be worth now
Here’s why the CSL (ASX:CSL) share price is up 5% in a month
How does the CSL (ASX:CSL) share price perform during lockdowns?
5 ASX shares to hold for 5 years

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
Trade The US Market With ZERO Brokerage* + FREE Access To Trading Ideas & Value Analysis Tools. Click Here!